Published in Lab Business Week, November 14th, 2004
Crucell reports revenues of EUR 4.1 million (US$5.1 million) for the third quarter 2004, which represents a significant increase over the EUR 1.2 million (US$1.4 million) in revenues the company reported for the same quarter last year.
"We have continued to attract new licensees and partners at a record rate, while making significant advances in moving our own portfolio of products towards clinical development," said Ronald Brus, MD, Crucell's chief executive officer.
Brus said the company's flu vaccine partnership with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week